Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis.

Abstract

OBJECTIVES: Troglitazone is a thiazolidinedione and peroxisome proliferator-activated receptor gamma (PPARgamma) ligand used to treat diabetes mellitus type II. Because hyperinsulinemia may be a factor in nonalcoholic steatohepatitis (NASH), we postulated that troglitazone could have beneficial effects in this disorder. Our study was initiated before reports of idiosyncratic hepatitis induced by this agent and was completed before its recent withdrawal from the market. METHODS: We studied 10 female patients (age 44 +/- 16) with histological NASH. All but two were obese (mean body mass index, BMI = 38 +/- 6). One had type 2 diabetes, and three had well-compensated cirrhosis with NASH. Troglitazone was given at a dose of 400 mg/day for < or = 6 months. Responders (defined as normal ALT at the end of treatment) were rebiopsied. Paired specimens were compared in blinded fashion. Mitochondria were quantitated using ultrathin electron microscopy. RESULTS: Seven of ten patients responded with normal ALT at the end of treatment. One of three nonresponders initially normalized ALT but returned to pretreatment level at 3 months. In this patient, therapy was stopped, and the ALT has remained at the baseline level with no other clinical or laboratory findings. In the responders, ALT fell from 87 +/- 38 before to 39 +/- 9 at the end of treatment (p = 0.01), and AST decreased from 77 +/- 23 to 30 +/- 8 (p = 0.002). Biopsy comparisons before and after therapy showed persistent steatohepatitis in all cases, although four of seven showed a one-point improvement in the necroinflammatory grade. Electron microscopy revealed elongation of the mitochondria after therapy. CONCLUSIONS: Normal ALT was seen in 70% of NASH patients at the end of treatment, but this biochemical response was associated with only mild histological improvement, and all follow-up biopsies had evidence of NASH. Normalization of the liver enzymes in patients with NASH who are treated with thiazolidinediones should be viewed with reservation. Follow-up biopsy is essential to evaluate the efficacy of these agents, which, at the histological level, appears to be relatively modest.

Overview

Integrity signals

Registry

Crossref · 10.1111/j.1572-0241.2001.03553.x

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 49 references

Research works printed but not linked: 9

  1. Komers R., 1998, Physiol Res, 47, 215
  2. 10.1210/en.139.1.428 · doi:10.1210/en.139.1.428
  3. Newsome P.N., 1999, Hepatology, 30, 438A
  4. Feldmann G., 1999, Hepatology, 30, 416A
  5. Coyle W.J., 1999, Gastroenterology, 116, A1198
  6. Menon K.V.N., Am J Gastroenterol
  7. Wise J., 1997, BMJ, 315, 1564
  8. 10.1016/S0002-9270(99)00433-5 · doi:10.1016/s0002-9270(99)00433-5 · Paper page
  9. Kronenberger B., 1999, Hepatology, 30, 459A

Cited by

See all 394

Metadata

Authors
Caldwell, S. H., Hespenheide, E. E., Redick, J. A., Iezzoni, J. C., Battle, E. H., & Sheppard, B. L.
Affiliations
University of Virginia (US)
Corresponding author
Caldwell, Stephen H
Venue
American Journal of Gastroenterology
Published
2001-02
Volume
96
Issue
2
Pages
519-525
ISSN
0002-9270 (ISSN-L)
OpenAlex
W2006591225
Cited by
394
References
49
Citations by year
2025: 2 · 2024: 1 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 7 · 2019: 3 · 2018: 4 · 2017: 7 · 2016: 5 · 2015: 8 · 2014: 5 · 2013: 9 · 2012: 5
FWCI
32.43
Type
journal article
Language
en
Open access
closed
Locations
  • The American Journal of Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
Funders
University of Virginia
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords
troglitazone, thiazolidinediones, nonalcoholic steatohepatitis, PPARγ, hyperinsulinemia, liver enzymes, ALT normalization, liver biopsy histology, mitochondrial ultrastructure, liver cirrhosis, obesity, drug safety
MeSH terms
Troglitazone, Adult, Alanine Transaminase, Chromans, Fatty Liver, Female, Humans, Hypoglycemic Agents, Obesity, Pilot Projects, Thiazoles, Thiazolidinediones

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. https://app.cochat.ai/papers/10.1111/j.1572-0241.2001.03553.x
The paper
Caldwell, S. H., Hespenheide, E. E., Redick, J. A., Iezzoni, J. C., Battle, E. H., & Sheppard, B. L. (2001). A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. American Journal of Gastroenterology. https://doi.org/10.1111/j.1572-0241.2001.03553.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.